Critical Contrast: Eloxx Pharmaceuticals (ELOX) & Its Competitors

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Eloxx Pharmaceuticals to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Risk and Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.17, meaning that their average share price is 417% less volatile than the S&P 500.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.86
Eloxx Pharmaceuticals Competitors	$3.50 billion	$3.13 billion	547.42

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Eloxx Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7598	13660	25483	1002	2.42

Eloxx Pharmaceuticals currently has a consensus target price of $38.33, indicating a potential upside of 129.13%. As a group, “Pharmaceuticals” companies have a potential upside of 26.44%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.38%	-223.56%	-16.98%

Summary

Eloxx Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.